Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$5.35 +2.3%	$4.70	$1.00 ▼ $7.00	$47.45M	0.67	225,929 shs	4,541 shs
CTMX CytomX Therapeutics	$1.90 +7.7%	$2.36	$0.40 ▼ $3.10	$152.78M	2.13	3.24 million shs	4.92 million shs
EPRX Eupraxia Pharmaceuticals	$5.33 +0.9%	$5.04	$2.20 ▼ $6.20	$191.49M	1.5	13,419 shs	2,099 shs
GNFT GENFIT	$3.93 -4.5%	$3.89	$2.55 ▼ $6.42	$196.30M	1.14	8,885 shs	752 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	+1.75%	-1.51%	+17.00%	+31.08%	+284.56%
CTMX CytomX Therapeutics	-0.56%	-16.19%	-26.67%	-13.30%	+51.72%
EPRX Eupraxia Pharmaceuticals	-3.12%	-1.51%	-1.29%	+37.50%	+102.30%
GNFT GENFIT	+3.53%	+7.87%	+8.62%	-1.91%	+3.01%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	3.1172 of 5 stars	3.3	5.0	0.0	3.8	1.7	0.0
CTMX CytomX Therapeutics	3.9686 of 5 stars	3.5	1.0	4.7	1.1	1.7	1.3
EPRX Eupraxia Pharmaceuticals	1.9806 of 5 stars	3.6	1.0	0.0	1.6	0.0	0.6
GNFT GENFIT	2.1281 of 5 stars	3.5	3.0	0.0	3.3	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	124.34% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.75	203.43% Upside
EPRX Eupraxia Pharmaceuticals	3.17	Buy	$11.00	106.57% Upside
GNFT GENFIT	3.00	Buy	$13.00	231.13% Upside

Current Analyst Ratings Breakdown

Latest ATHE, GNFT, CTMX, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2025	CTMX CytomX Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
7/24/2025	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$11.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
CTMX CytomX Therapeutics	$138.10M	1.11	$0.39 per share	4.90	$1.49 per share	1.27
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	$76.77M	2.56	$0.07 per share	58.30	$1.50 per share	2.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	$31.87M	$0.56	3.38	N/A	N/A	34.04%	158.70%	36.04%	N/A
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.85	N/A	N/A	N/A	N/A	-715.66%	-128.13%	N/A
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ATHE, GNFT, CTMX, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	EPRX Eupraxia Pharmaceuticals	-$0.21	-$0.26	-$0.05	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
CTMX CytomX Therapeutics	N/A	4.20	4.20
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
GNFT GENFIT	0.08	1.23	1.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
CTMX CytomX Therapeutics	67.77%
EPRX Eupraxia Pharmaceuticals	N/A
GNFT GENFIT	2.24%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
CTMX CytomX Therapeutics	6.60%
EPRX Eupraxia Pharmaceuticals	N/A
GNFT GENFIT	4.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
CTMX CytomX Therapeutics	170	80.62 million	75.30 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable

ATHE, GNFT, CTMX, and EPRX Headlines

Recent News About These Companies

GENFIT (NASDAQ:GNFT) Stock Price Down 3.4% - Time to Sell?

August 1, 2025 | marketbeat.com

Kepler Capital Maintained a Buy Rating on Genfit (GNFT)

July 28, 2025 | msn.com

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial - The Manila Times

July 9, 2025 | manilatimes.netM

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

July 8, 2025 | globenewswire.com

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

June 17, 2025 | globenewswire.com

GENFIT S.A.: GENFIT Reports First Quarter 2025 Financial Information

May 23, 2025 | finanznachrichten.de

GENFIT Reports First Quarter 2025 Financial Information

May 22, 2025 | globenewswire.com

GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo® in Italy

May 20, 2025 | globenewswire.com

GENFIT S.A.: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 15, 2025 | finanznachrichten.de

GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year 2024)

May 14, 2025 | globenewswire.com

Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks

May 12, 2025 | seekingalpha.com

GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Preparatory Documents

May 7, 2025 | globenewswire.com

GENFIT to Present Latest ACLF Research at EASL Congress 2025

May 5, 2025 | globenewswire.com

GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F

April 29, 2025 | globenewswire.com

GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025

April 28, 2025 | globenewswire.com

GENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

April 25, 2025 | finanznachrichten.de

GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update

April 24, 2025 | globenewswire.com

GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders

March 20, 2025 | globenewswire.com

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week

March 14, 2025 | msn.com

Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

March 10, 2025 | globenewswire.com

GENFIT Announces Revenues and Cash Position as of December 31, 2024

February 27, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATHE, GNFT, CTMX, and EPRX Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$5.35 +0.12 (+2.28%)

As of 02:55 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

CytomX Therapeutics NASDAQ:CTMX

$1.90 +0.14 (+7.67%)

As of 03:02 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.32 +0.05 (+0.85%)

As of 02:31 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

GENFIT NASDAQ:GNFT

$3.93 -0.18 (-4.48%)

As of 02:58 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time